Buscopan IBS Relief

Each tablet contains hyoscine as 10 mg of hyoscine butylbromide.

For excipients, see section 6.1.

Coated tablets.

Buscopan IBS Relief tablets are indicated for the relief of gastro- intestinal tract spasm associated with medically confirmed Irritable Bowel Syndrome.

Buscopan IBS Relief tablets should be swallowed whole with adequate water.

Adults and Children 12 years or over:

The recommended starting dose is 1 tablet three times daily; this can be increased up to 2 tablets four times daily if necessary.

Children under 12 years:

Not recommended.

No specific information on the use of this product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group have been reported.

Buscopan IBS Relief tablets should not be administered to patients with myasthenia gravis, megacolon and narrow angle glaucoma. In addition, they should not be given to patients with a known hypersensitivity to hyoscine butylbromide or any other component of the product.

Buscopan IBS Relief tablets should be used with caution in conditions characterised by tachycardia such as thyrotoxicosis, cardiac insufficiency or failure and in cardiac surgery where it may further accelerate the heart rate.

Due to the risk of anticholinergic complications, caution should also be used in patients susceptible to intestinal or urinary outlet obstructions.

Because of the possibility that anticholinergics may reduce sweating, Buscopan IBS Relief tablets should be administered with caution to patients with pyrexia.

Elevation of intraocular pressure may be produced by the administration of anticholinergic agents such as hyoscine butylbromide in patients with undiagnosed and therefore untreated narrow angle glaucoma. Therefore, patients should seek urgent ophthalmological advice if they develop a painful, red eye with loss of vision whilst, or after taking, Buscopan IBS Relief tablets.

As the tablet coating contains a small quantity of sucrose (41.2 mg), patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take Buscopan IBS Relief.

Special warnings to be included in the Patient Information Leaflet:

Only take Buscopan IBS Relief if your doctor has diagnosed Irritable Bowel Syndrome.

If any of the following now apply to you, you must not use Buscopan IBS Relief without first discussing it with your doctor, even if you know you have IBS.

• if you are 40 years or over and it is some time since your last attack of IBS or the symptoms are different this time.

• if you have recently passed blood from the bowel

• if you suffer from severe constipation

• if you are feeling sick or vomiting

• if you have lost your appetite or lost weight

• if you have difficulty or pain passing urine

• if you have a fever

• if you have recently travelled abroad

Consult your doctor if you develop new symptoms, or if your symptoms worsen or have not improved over two weeks.

The anticholinergic effect of drugs, for example tricyclic antidepressants, antihistamines, quinidine, amantadine, butyrophenones, phenothiazines, disopyramide and anticholinergic drugs (e.g. tiotropium, ipratropium) may be intensified by Buscopan IBS Relief tablets.

Concomitant treatment with dopamine antagonists such as metoclopramide may result in diminution of the effects of both drugs on the gastrointestinal tract.

The tachycardic effects of beta-adrenergic agents may be enhanced by Buscopan IBS Relief tablets.

Pregnancy

There are limited data from the use of hyoscine butylbromide in pregnant women. Animal studies are insufficient with respect to reproductive toxicity (see section 5.3). As a precautionary measure Buscopan is not recommended during pregnancy.

Lactation

There is insufficient information on the excretion of hyoscine butylbromide and its metabolites in human milk. A risk to the breastfeeding child cannot be excluded. Use of Buscopan during breastfeeding is not recommended.

Fertility

No studies on the effects on human fertility have been conducted.

No studies on the effects on the ability to drive and use machines have been performed.

Because of possible visual accommodation disturbances patients should not drive or operate machinery if affected.

Many of the undesirable effects can be assigned to the anticholinergic property of Buscopan IBS Relief.

Adverse events have been ranked under headings of frequency using the following convention:

Very common ( 1/10); common ( 1/100, < 1/10); uncommon ( 1/1000, <1/100); rare ( 1/10000, <1/1000); very rare (<1/10000). Not known – incidence cannot be estimated from the available data.

Symptoms:

Serious signs of poisoning following acute overdosage have not been observed in man. In the case of overdosage, anticholinergic effects such as urinary retention, dry mouth, reddening of the skin, tachycardia, inhibition of gastrointestinal motility and transient visual disturbances may occur, and Cheyne-Stokes respiration has been reported.

Therapy:

In the case of oral poisoning, gastric lavage with medicinal charcoal should be followed by magnesium sulphate (15%). Symptoms of Buscopan IBS Relief tablets overdosage respond to parasympathomimetics. For patients with glaucoma, pilocarpine should be given locally. Cardiovascular complications should be treated according to usual therapeutic principles. In case of respiratory paralysis, intubation and artificial respiration should be considered. Catheterisation may be required for urinary retention.

In addition, appropriate supportive measures should be administered as required.

Buscopan IBS Relief tablets exert a spasmolytic action on the smooth muscle of the gastrointestinal, biliary and genito-urinary tracts. As a quaternary ammonium derivative, hyoscine butylbromide does not enter the central nervous system. Therefore, anticholinergic side effects at the central nervous system do not occur. Peripheral anticholinergic action results from a ganglion-blocking action within the visceral wall as well as from an anti-muscarinic activity.

Following oral and intravenous administration, hyoscine butylbromide concentrates in the tissue of the gastrointestinal tract, liver and kidneys. As a quaternary ammonium derivative, hyoscine butylbromide does not pass the blood-brain barrier or enter the central nervous system.

Following oral administration, hyoscine butylbromide is only partially absorbed. Nevertheless, despite the briefly measurable low blood levels, hyoscine butylbromide remains available at the site of action because of its high tissue affinity.

In limited reproductive toxicity studies hyoscine butylbromide showed no evidence of teratogenicity in rats at 200 mg/kg in the diet or in rabbits at 200 mg/kg by oral gavage or 50 mg/kg by subcutaneous injection. Fertility in the rat was not impaired at doses up to 200 mg/kg in the diet.

Calcium Hydrogen Phosphate

Maize Starch

Starch, Soluble

Colloidal Silica

Tartaric Acid

Stearic Acid

Coating:

Sucrose

Talc

Acacia

Titanium Dioxide

Macrogol 6000

Carnauba Wax

White Beeswax

Povidone

None stated.

Five years

Do not store above 25°C.

Keep in the original packaging.

Buscopan IBS Relief tablets are in blister packs of 10, 12, 20 and 24.

Not all pack sizes may be marketed.

None stated.

Boehringer Ingelheim Limited

Ellesfield Avenue

Bracknell

Berkshire

RG12 8YS

United Kingdom

Trading as:

Boehringer Ingelheim Consumer Healthcare

PL 00015/0253

27^th March 2001 / 2^nd August 2006

January 2012